These two CTLA-4-Ig molecules have been investigated in multiple autoimmune disorders, including RA, T1DM, diffuse cutaneous systemic sclerosis (dcSSc), psoriasis, and SLE. This evidence concerns the gene CTLA4 and rheumatoid arthritis.